Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations

v3.23.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating expenses:    
Research and development $ 5,295 $ 12,725
General and administrative 3,563 3,254
Total operating expenses 8,858 15,979
Loss from operations (8,858) (15,979)
Other income (expense):    
Interest income, net 87 34
Change in fair value of warrant liabilities 7,400 (4,212)
Total other income (expense) 7,487 (4,178)
Net loss $ (1,371) $ (20,157)
Per share information:    
Basic net loss per share $ (0.69) $ (41)
Weighted average shares outstanding basic 1,975,476 491,626
Diluted net loss per share $ (0.69) $ (41)
Weighted average shares outstanding diluted 1,975,476 491,626